

DAFTAR PUSTAKA

- Al-Nandy, M. and Alshenay, A. (2018) 'Immunohistochemical Expression of Androgen and Estrogen Receptors', *Diagnostic Pathology: Open Access*, 03(03). doi: 10.4172/2476-2024.100014.
- Andreassen, B.K., Aagnes, B., Gislefoss, R., Andreassen, M., Wahlqvist, R., 2016. Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981-2014. *BMC Cancer* 16, 799. <https://doi.org/10.1186/s12885-016-2832-x>
- Boorjian, S., Ugras, S., Mongan, N.P., Gudas, L.J., You, X., Tickoo, S.K., et al., 2004. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. *Urology* 64: 383–388. doi:10.1016/j.urology.2004.03.025
- Carneiro, B.A., Meeks, J.J., Kuzel, T.M., Scaranti, M., Abdulkadir, S.A., Giles, F.J., 2015. Emerging therapeutic targets in bladder cancer. *Cancer Treat. Rev.* 41, 170–178. <https://doi.org/10.1016/j.ctrv.2014.11.003>
- Chou, R., Gore, J.L., Buckley, D., Fu, R., Gustafson, K., Griffin, J.C., Grusing, S., Selph, S., 2015. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis. *Ann. Intern. Med.* 163, 922–931. <https://doi.org/10.7326/M15-0997>
- Cumberbatch, M.G.K., Jubber, I., Black, P.C., Esperto, F., Figueroa, J.D., Kamat, A.M., et al., 2018. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. *Eur. Urol.* 74: 784–795. doi:10.1016/j.eururo.2018.09.001
- Ghosh, M., Brancato, S.J., Agarwal, P.K., Apolo, A.B., 2014. Targeted therapies in urothelial carcinoma. *Curr Opin Oncol* 26, 305–320. <https://doi.org/10.1097/CCO.0000000000000064>
- Grégoire, M., Fradet, Y., Meyer, F., Têtu, B., Bois, R., Bédard, G., Charrois, R., Naud, A., 1997. Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. *J. Urol.* 157, 1660–1664.
- Humphrey, P.A., Moch, H., Cubilla, A.L., Ulbright, T.M., Reuter, V.E., 2016. WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. *Eur Urol.* Jul;70(1). P106-119.
- Izumi, K., Taguri, M., Miyamoto, H., Hara, Y., Kishida, T., Chiba, K., Murai, T., Hirai, K., Suzuki, K., Fujinami, K., Ueki, T., Udagawa, K., Kitami, K., Moriyama, M., Miyoshi, Y., Tsuchiya, F., Ikeda, I., Kobayashi, K., Sato, M., Morita, S., Noguchi, K., Uemura, H., 2014. Androgen deprivation therapy prevents bladder cancer recurrence. *Oncotarget* 5, 12665–12674. <https://doi.org/10.18632/oncotarget.2851>
- Jakse, G., Hall, R., Bono, A., Höftl, W., Carpentier, P., Spaander, J.P., van der Meijden, A.P., Sylvester, R., 2001. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. *Eur. Urol.* 40, 144–150. <https://doi.org/10.1159/000049765>

- Jeong, C.W., Jeon, H.G., Kwak, C., Jeong, H., & Lee, S.E., 2005. Comparison of 30 mg and 40 mg of Mitomycin C Intravesical Instillation in Korean Superficial Bladder Cancer Patients: Prospective, Randomized Study. *Cancer Res. Treat.* 37: 44. doi:10.4143/crt.2005.37.1.44
- Jing, Y.; Cui, D.; Guo, W.; Jiang, J.; Jiang, B.; Lu, Y.; Zhao, W.; Wang, X.; Jiang, Q.; Han, B. 2014. Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition. *Cancer Lett.* 348, 135–145.
- Jonathan, I.E., Tamara, L.L. 2015. Robin cottran 9th profesional edition. Chapter 21: The Lower Urinary Tract and Male Genital System. Elsevier. P859-990
- Kashiwagi, E. et al. (2016) ‘Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract’, *Cancer Biology and Therapy*. Taylor & Francis, 17(11), pp. 1188–1196. doi: 10.1080/15384047.2016.1235667.
- Kim B, Semelka RC, Ascher SM, et al. Bladder tumor *staging*: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. *Radiology* 1994; 193:239.
- Knowles, M.A., Hurst, C.D., 2015. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. *Nat. Rev. Cancer* 15, 25–41. <https://doi.org/10.1038/nrc3817>
- Lombard A.P., Mudryj M., 2015. The emerging role of the androgen receptor in bladder cancer. *Society for Endocrinology*. 22, 65-277
- Li, P., Chen, J., Miyamoto, H., 2017. Androgen Receptor Signaling in Bladder Cancer. *Cancers (Basel)* 9. <https://doi.org/10.3390/cancers9020020>
- Lin C, Yin Y, Stemler K, Humphrey P, Kibel AS, Mysorekar IU & Ma L 2013 Constitutive b-catenin activation induces male-specific tumorigenesis in the bladder urothelium. *Cancer Research* 73 5914–5925. doi:10.1158/0008-5472.CAN-12-4198
- Lombard, A.P., Mudryj, M., 2015. The emerging role of the androgen receptor in bladder cancer. *Endocr. Relat. Cancer* 22, R265-277. <https://doi.org/10.1530/ERC-15-0209>
- Lopez-Beltran, A., Henriques, V., Montironi, R., Cimadamore, A., Raspollini, M.R., & Cheng, L., 2019. Variants and new entities of bladder cancer. *Histopathology* 74: 77–96. doi:10.1111/his.13752
- Mir, C., Shariat, S.F., Van Der Kwast, T.H., Ashfaq, R., Lotan, Y., Evans, A., et al., 2011. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: A large multi-institutional study. *BJU Int.* 108: 24–30. doi:10.1111/j.1464-410X.2010.09834.x
- Miyamoto, H., Yang, Z., Chen, Y.-T., Ishiguro, H., Uemura, H., Kubota, Y., Nagashima, Y., Chang, Y.-J., Hu, Y.-C., Tsai, M.-Y., Yeh, S., Messing, E.M., Chang, C., 2007. Promotion of bladder cancer development and progression by androgen receptor signals. *J. Natl. Cancer Inst.* 99, 558–568. <https://doi.org/10.1093/jnci/djk113>

- Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ & Yeh S 2012 Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. *BJU International* 109 1716–1726. doi:10.1111/j.1464-410X.2011.10706.x
- Mizushima, T., Tirador, K.A., Miyamoto, H. 2017. Androgen receptor activation: A prospective therapeutic target for bladder cancer?. <http://dx.doi.org/10.1080/14728222.2017.1280468>.
- Mizushima, T., Tirador, K.A., Miyamoto, H., 2017. Androgen receptor activation: a prospective therapeutic target for bladder cancer? *Expert Opin. Ther. Targets* 21, 249–257. <https://doi.org/10.1080/14728222.2017.1280468>
- Molina-Cerrilo, Martinez-Saez, Alonzo-Gordoa, Tirado-Zambrano, Delgado-Vargas, Earl, et al. Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach? *Clinical Genitourinary Cancer*. 2015;13(6).p.493-8.
- Mumtaz S., Hussain Z., Janjua T.k., et al. 2020. Androgen recetpro: evaluation and correlation with recurrence and clinicopathological parameters in papillary urothelial carcinomas of the urinary bladder. *Cureus*. 12: 6715. doi: 10.7759/cureus.6715
- Murphy, Gignon, Perlman. Tumors of the Urinary Bladder. In: Tumors of the Kidney, Bladder, and Related Urinary Structure. AFIP Atlas of Tumor Pathology Series 4. Washington DC: American Registry of Pathology; 2004. p.241-329.
- Ordonez, Rosai. Urinary Tract. In : Rosai, editor. Rosai and Ackermann's Surgical Pathology. 10th ed. Edinburgh : Mosby Elsevier, 2011. p.1257-1270.
- Ploeg, M., Aben, K.K.H., & Kiemeney, L.A., 2009. The present and future burden of urinary bladder cancer in the world. *World J. Urol.* 27: 289–293. doi:10.1007/s00345-009-0383-3
- Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P., Padala, S. A., & Barsouk, A. 2020. Epidemiology of Bladder Cancer. *Medical sciences (Basel, Switzerland)*, 8(1), 15. <https://doi.org/10.3390/medsci8010015>
- Schatz, P. Gross Anatomy of Urine Transport · Anatomy and Physiology. OpenStax College, Anatomy and Physiology. OpenStax CNX. <http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e22@11.1>. (2020). Available at: <https://philschatz.com/anatomy-book/contents/m46427.html>. (Accessed: 9th October 2020)
- Shah, R. B., Montgomery, J. S., Montie, J. E. & Kunju, L. P. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: Impact of mandatory central pathology review at a large referral hospital. *Urol. Oncol. Semin. Orig. Investig.* **31**, 1650–1655 (2013).
- Shiota, M., Takeuchi, A., Yokomizo, A., Kashiwagi, E., Tatsugami, K., Kuroiwa, K., Naito, S., 2012. Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. *J. Urol.* 188, 276–286. <https://doi.org/10.1016/j.juro.2012.02.2554>
- Sievert, K.D., Amend, B., Nagele, U., Schilling, D., Bedke, J., Horstmann, M., Hennenlotter, J., Kruck, S., Stenzl, A., 2009. Economic aspects of bladder

- cancer: what are the benefits and costs? *World J Urol* 27, 295–300.
<https://doi.org/10.1007/s00345-009-0395-z>
- Sikic, D., Breyer, J., Hartmann, A., Burger, M., Erben, P., Denzinger, S., Eckstein, M., Stöhr, R., Wach, S., Wullich, B., Keck, B., Wirtz, R.M., Otto, W., 2017. High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. *Transl Oncol* 10, 340–345.
<https://doi.org/10.1016/j.tranon.2017.01.013>
- Smith, N.D., Prasad, S.M., Patel, A.R., Weiner, A.B., Pariser, J.J., Razmaria, A., Maene, C., Schuble, T., Pierce, B., Steinberg, G.D., 2016. Bladder Cancer Mortality in the United States: A Geographic and Temporal Analysis of Socioeconomic and Environmental Factors. *J. Urol.* 195, 290–296.
<https://doi.org/10.1016/j.juro.2015.07.091>
- Torres-Estay, V., Carreño, D.V., San Francisco, I.F., Sotomayor, P., Godoy, A.S., Smith, G.J., 2015. Androgen receptor in human endothelial cells. *J. Endocrinol.* 224, R131–137. <https://doi.org/10.1530/JOE-14-0611>
- Von Der Maase, H., Sengelov, L., Roberts, J.T., Ricci, S., Dogliotti, L., Oliver, T., et al., 2005. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. *J. Clin. Oncol.* 23: 4602–4608.
doi:10.1200/JCO.2005.07.757
- Westhoff, E., Maria De Oliveira-Neumayer, J., Aben, K.K., Vrieling, A., & Kiemeny, L.A., 2016. Low awareness of risk factors among bladder cancer survivors: New evidence and a literature overview. *Eur. J. Cancer* 60: 136–145. doi:10.1016/j.ejca.2016.03.071
- Knowles, M.A., Hurst, C.D., 2015. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. *Nat Rev Cancer* 15, 25–41.
<https://doi.org/10.1038/nrc3817>
- Wu, J.-T., Han, B.-M., Yu, S.-Q., Wang, H.-P., Xia, S.-J., 2010. Androgen Receptor Is a Potential Therapeutic Target for Bladder Cancer. *Urology* 75, 820–827. <https://doi.org/10.1016/j.urology.2009.10.041>
- Zhuang, Y.H.; Bläuer, M.; Tammela, T.; Tuohimaa, P. 1997. Immunodetection of androgen receptor in human urinary bladder cancer. *Histopathology*, 30, 556–562.